Free Trial
→ Trump’s treachery (From Porter & Company) (Ad)
NYSE:CYBN

Cybin 11/14/2023 Earnings Report

Cybin logo
$8.24 +0.14 (+1.67%)
As of 12:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.05
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
May 22, 2025 | businesswire.com
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
May 15, 2025 | businesswire.com
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
May 29, 2025 | Colonial Metals (Ad)
Cybin secures new patent for depression treatment drug
May 9, 2025 | investing.com
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
April 23, 2025 | businesswire.com
Cybin initiated with a Buy at Guggenheim
March 12, 2025 | markets.businessinsider.com
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NYSE:CYBN), a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

View Cybin Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles